Opinion
Video
Author(s):
Panelists discuss how they will explore optimizing care for patients with ALK-positive non-small cell lung cancer (ALK+ NSCLC) through treatment selection, sequencing strategies, and interpretation of emerging clinical data.
Panel Introduction
This summary is based on an AJMC Peer Exchange program titled “Advancing ALK+ NSCLC Care: Optimizing Treatment, Sequencing, and Long-Term Outcomes,” featuring the following experts:
Introduction and Treatment Landscape Evolution
Program Overview
The panelists explore strategies for optimizing care of patients with ALK-positive non–small cell lung cancer through evidence-based treatment selection, sequencing approaches, and interpretation of emerging clinical data to improve long-term outcomes.